{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:41:17Z","timestamp":1794948077291,"version":"4.9.1"},"reference-count":58,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Chemotherapy results in a short median time to next treatment in patients with mycosis fungoides\/S\u00e9zary syndrome. \u03b1-interferon achieves a superior time to next treatment compared with chemotherapy, regardless of stage.<\/jats:p>","DOI":"10.1182\/blood-2014-07-588236","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T05:57:25Z","timestamp":1413957445000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":213,"title":["Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy"],"prefix":"10.1182","volume":"125","author":[{"given":"Charlotte F. M.","family":"Hughes","sequence":"first","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khot","sequence":"additional","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McCormack","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;"},{"name":"Department of Dermatology, St. Vincent\u2019s Hospital Department of Medicine, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lade","sequence":"additional","affiliation":[{"name":"Division of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Westerman","sequence":"additional","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;"},{"name":"Division of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Twigger","sequence":"additional","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odette","family":"Buelens","sequence":"additional","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Newland","sequence":"additional","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Tam","sequence":"additional","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Ryan","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Wood","sequence":"additional","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia;"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2019111819075485800_B1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas.","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2019111819075485800_B2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"issue":"8","key":"2019111819075485800_B3","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2105\/AJPH.89.8.1240","article-title":"Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality.","volume":"89","author":"Weinstock","year":"1999","journal-title":"Am J Public Health"},{"issue":"6","key":"2019111819075485800_B4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"31","key":"2019111819075485800_B5","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal.","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111819075485800_B6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/10428194.2013.790541","article-title":"Prognostic factors and risk stratification in early mycosis fungoides.","volume":"55","author":"Vonderheid","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2019111819075485800_B7","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009.","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6 Pt 1","key":"2019111819075485800_B8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/S\u00e9zary syndrome.","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2019111819075485800_B9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and s\u00e9zary syndrome: a stage-based approach.","volume":"6","author":"Horwitz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"2019111819075485800_B10","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome.","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"issue":"Suppl 6","key":"2019111819075485800_B11","doi-asserted-by":"crossref","first-page":"vi149","DOI":"10.1093\/annonc\/mdt242","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"24","author":"Willemze","year":"2013","journal-title":"Ann Oncol"},{"key":"2019111819075485800_B12","first-page":"CD008946","article-title":"Interventions for mycosis fungoides.","volume":"9","author":"Weberschock","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"20","key":"2019111819075485800_B13","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-07-202895","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome.","volume":"114","author":"Prince","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111819075485800_B14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"2019111819075485800_B15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2340\/0001555560542544","article-title":"Combination chemotherapy in the tumour stage of mycosis fungoides with cyclophosphamide, vincristine, vp-16, adriamycin and prednisolone (cop, chop, cavop): a report from the Scandinavian mycosis fungoides study group.","volume":"60","author":"Molin","year":"1980","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"2019111819075485800_B16","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.1994.12.10.2051","article-title":"Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides\/S\u00e9zary syndrome.","volume":"12","author":"Foss","year":"1994","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111819075485800_B17","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2133.2001.04191.x","article-title":"A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.","volume":"144","author":"Scarisbrick","year":"2001","journal-title":"Br J Dermatol"},{"issue":"11","key":"2019111819075485800_B18","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"issue":"13","key":"2019111819075485800_B19","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111819075485800_B20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111819075485800_B21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"2019111819075485800_B22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients.","volume":"49","author":"Zackheim","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2019111819075485800_B23","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients.","volume":"34","author":"Zackheim","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2019111819075485800_B24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"33","key":"2019111819075485800_B25","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012.","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111819075485800_B26","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","article-title":"Infections complicating mycosis fungoides and S\u00e9zary syndrome.","volume":"267","author":"Axelrod","year":"1992","journal-title":"JAMA"},{"issue":"4","key":"2019111819075485800_B27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma.","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"issue":"9","key":"2019111819075485800_B28","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111819075485800_B29","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome.","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"issue":"21","key":"2019111819075485800_B30","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111819075485800_B31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"29","key":"2019111819075485800_B32","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111819075485800_B33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/fon.09.36","article-title":"Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.","volume":"5","author":"Prince","year":"2009","journal-title":"Future Oncol"},{"issue":"2","key":"2019111819075485800_B34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -na\u00efve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"key":"2019111819075485800_B35","author":"Pohlman"},{"issue":"12","key":"2019111819075485800_B36","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H.","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111819075485800_B37","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"2019111819075485800_B38","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111819075485800_B39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.clml.2013.02.020","article-title":"Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.","volume":"13","author":"Duvic","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2019111819075485800_B40","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111819075485800_B41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0781.2012.00689.x","article-title":"Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis.","volume":"28","author":"Knobler","year":"2012","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"7","key":"2019111819075485800_B42","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma.","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111819075485800_B43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.bmt.1704641","article-title":"Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation.","volume":"34","author":"Herbert","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111819075485800_B44","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/archderm.138.10.1359","article-title":"Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma.","volume":"138","author":"Guitart","year":"2002","journal-title":"Arch Dermatol"},{"issue":"29","key":"2019111819075485800_B45","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111819075485800_B46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2012.06.002","article-title":"Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review.","volume":"85","author":"Schlaak","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"2019111819075485800_B47","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111819075485800_B48","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation.","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111819075485800_B49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111819075485800_B50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2012.09.004","article-title":"Management of indolent lymphoma: where are we now and where are we going.","volume":"26","author":"Lunning","year":"2012","journal-title":"Blood Rev"},{"issue":"19","key":"2019111819075485800_B51","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood-2010-03-275800","article-title":"Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.","volume":"116","author":"Harousseau","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111819075485800_B52","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2019111819075485800_B53","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","article-title":"Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S\u00e9zary syndrome.","volume":"123","author":"Querfeld","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111819075485800_B54","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia.","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111819075485800_B55","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdu231","article-title":"Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and S\u00e9zary syndrome).","volume":"25","author":"Dummer","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111819075485800_B56","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ctrv.2006.08.006","article-title":"Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.","volume":"33","author":"Whittaker","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"2019111819075485800_B57","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-5-24","article-title":"Novel therapeutic agents for cutaneous T-Cell lymphoma.","volume":"5","author":"Jain","year":"2012","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2019111819075485800_B58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions.","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/1\/71\/1383658\/71.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/1\/71\/1383658\/71.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T12:55:29Z","timestamp":1689598529000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/1\/71\/33930\/Lack-of-durable-disease-control-with-chemotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-07-588236","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,1]]}}}